How much funding has Craif raised?

Craif has raised $22.0M in total funding, most recently a Series C round.

Who are Craif's investors?

Craif's investors include X&KSK, Daiwa Corporate Investment, ANRI, Hakuhodo DY Ventures.

Where is Craif headquartered?

Craif is headquartered in Nagoya, Japan.

What industry is Craif in?

Craif operates in Artificial Intelligence, Biotech, Healthcare.

Craif

Nagoya, Japan · Founded 2018 · $22.0M raised

Artificial Intelligence

Biotech

Healthcare

Headquarters: Nagoya
Employees: 11–50
Founded: 2018
Business Model: B2B

Website: craif.com
Total Funding: $22.0M
Last Round: $22.0M Series CApr 2025
Rounds: 4

About

Craif is a Japanese biotech company spun out of Nagoya University in 2018, pioneering non-invasive early cancer detection through urinary microRNA analysis. The company's proprietary biomarker platform, NANO IP (NANO Intelligence Platform), combines advanced microfluidics, multi-microRNA profiling, and AI algorithms to detect cancer-specific signals in urine samples. Its flagship product, miSignal Scan, enables urine-based cancer risk screening developed through collaborative research with approximately 50 major Japanese university hospitals and cancer research centers. Craif expanded to the United States in 2025, establishing a bioAI lab in San Diego and being accepted into Johnson & Johnson's JLABS incubator. The company is advancing medical device development for pancreatic cancer early detection in both Japan and the US.

Summary

Craif is an Artificial Intelligence company based in Nagoya, Japan, founded in 2018. It has raised $22.0M in total across 4 rounds, most recently a $22.0M Series C round in Apr 2025. Investors include X&KSK, Daiwa Corporate Investment and ANRI.